Accreditation/
Credit Designation
Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
An application has been made to the EACCME® for CME accreditation of this event.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Illumina, Inc.
Virtual Tumor Board®: Global Perspectives on Comprehensive NGS Profiling to Personalize Treatment in Cancer

Activity Overview
Tumor biomarkers have transformed cancer care by identifying which patients might benefit from a particular therapy, thus pinpointing effective cancer treatments faster to improve patient outcomes. Questions remain, however, on what test to use, when to use it, and how to interpret the results. This live video webcast will unearth key clinical challenges and best practices in the management of multiple tumor types with next-generation sequencing (NGS) during a facilitated discussion between 2 medical oncologists, a pathologist, and a community oncologist. The case-based program is designed to help physicians assess NGS technologies, existing and emerging biomarkers; determine appropriate treatment based on patient and tumor characteristics; and apply novel management strategies to their practices to optimize outcomes for their patients.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Illumina, Inc.
Target Audience
This educational activity is directed toward an international audience of medical oncologists, pathologists, and fellows involved in the treatment and management of patients with cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of cancer may also participate.
Learning Objectives
Upon completion of this activity, participants will be able to:
- Discuss the rationale supporting the role of NGS-based tumor testing strategies in patients with cancer and advantages of NGS-based testing methodology in the era of evolving biomarker research
- Outline the role of current and emerging biomarkers in personalizing therapies in patients with cancer
- Recognize the role of the multidisciplinary team in executing, interpreting, and applying results of NGS-based testing in cancer care
- Utilize case-based approach to review the role of NGS-based technologies in improving outcomes for patients with cancer
Program Chair

Professor of Clinical Medicine
Director, Thoracic/Head and Neck Oncology
Director, Clinical Cancer Genomics
Albert Einstein College of Medicine/Montefiore Medical Center
Bronx, NY
Register
You must be logged in to PER to register for this meeting
Or Register for PER now
*Required Fields